Application of radiomics based on chest CT-enhanced dual-phase imaging in the immunotherapy of non-small cell lung cancer

Abstract

OBJECTIVE:

To explore the value of applying computed tomography (CT) radiomics based on different CT-enhanced phases to determine the immunotherapeutic efficacy of non-small cell lung cancer (NSCLC).

METHODS:

106 patients with NSCLC who underwent immunotherapy are randomly divided into training (74) and validation (32) groups. CT-enhanced arterial and venous phase images of patients before treatment are collected. Region-of-interest (ROI) is segmented on the CT-enhanced images, and the radiomic features are extracted. One-way analysis of variance and least absolute shrinkage and selection operator (LASSO) are used to screen the optimal radiomics features and analyze the association between radiomics features and immunotherapy efficacy. The area under receiver-operated characteristic curves (AUC) along with the sensitivity and specificity are computed to evaluate diagnostic effectiveness.

RESULTS:

LASSO regression analysis screens and selects 6 and 8 optimal features in the arterial and venous phases images, respectively. Applying to the training group, AUCs based on CT-enhanced arterial and venous phase images are 0.867 (95% CI:0.82–0.94) and 0.880 (95% CI:0.86–0.91) with the sensitivities of 73.91% and 76.19%, and specificities of 66.67% and 72.19%, respectively, while in validation group, AUCs of the arterial and venous phase images are 0.732 (95% CI:0.71–0.78) and 0.832 (95% CI:0.78–0.91) with sensitivities of 75.00% and 76.00%, and specificities of 73.07% and 75.00%, respectively. There are no significant differences between AUC values computed from arterial phases and venous phases images in both training and validation groups (P < 0.05).

CONCLUSION:

The optimally selected radiomics features computed from CT-enhanced different-phase images can provide new imaging marks to evaluate efficacy of the targeted therapy in NSCLC with a high diagnostic value.

Keywords

Radiomics non-small cell lung cancer computed tomography-enhanced immunotherapy curative effect evaluation

Get full access to this article

View all access options for this article.

References

Siegel

R.L.

, Miller

K.D.

, Jemal

, Cancer statistics, CA Cancer J Clin. 69(1) (2019), 7–34.

Qiu

, Xing

, Wang

et al. Development and validation of a radiomics nomogram using computed tomography for differentiating immune checkpoint inhibitor-related pneumonitis from radiation pneumonitis for patients with non-small cell lung cancer, Immunol 13 (2022), 870842.

Jemal

, Bray

, Center

M.M.

et al. Global cancer statistics, CA Cancer J Clin. 61(2) (2011), 69–90.

Sun

, Hu

, Ge

et al. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features, J Xray Sci Technol. 28(3) (2020), 449–459.

Mounessi

F.S.

, Eckardt

, Holstein

et al. Image-based lung functional radiotherapy planning for non-small cell lung cancer, Strahlenther Onkol. 196(2) (2020), 151–158.

Lin

L.Y.

, Zhang

, Suo

S.T.

et al. Correlation between dual-energy spectral CT imaging parameters and pathological grades of non-small cell lung cancer, Radiol. 73(4) (2018), 412.

Jiang

, Sun

, Guo

et al. Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result, Acad Radiol. 27(2) (2020), 171–179.

Lee

J.C.

, Hartnett

G.F.

, Ravi Kumar

A.S.

. The added benefit of contrast-enhanced CT in evaluation of incidental FDG-avid colon lesions, Eur J Nucl Med Mol Imaging. 47(10) (2020), 2244.

Zhou

, Jin

, Wang

et al. Clinical practice of epidermal growth factor receptor-tyrosine kinase inhibitor targeted drugs combined with gadolinium oxide nanoparticles in the treatment of non-small cell lung cancer, Bioengineered 13 (2022), 128–139.

10.

, Sun

, Fan

et al. Radiomics signature: A potential and incremental predictor for EGFR mutation status in NSCLC patients, comparison with CT morphology, , Lung Cancer 132 (2019), 28–35.

11.

Ganeshan

, Panayiotou

, Burnand

et al. Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival, Eur. Radiol. 22(4) (2022), 796–802.

12.

Gillies

R.J.

, Kinahan

P.E.

, Hricak

. Radiomics: images are more than pictures, they are data, Radiology 278(2) (2016), 563–577.

13.

Jain

, Khorrami

, Gupta

et al. Novel non-invasive radiomic signature on CT scans predicts response to platinum-based chemotherapy and is prognostic of overall survival in small cell lung cancer, , Front Oncol. 11 (2021), 744724.

14.

Ladwa

, Roberts

K.E.

, O’Leary

et al. Computed tomography texture analysis of response to second-line nivolumab in metastatic non-small cell lung cancer, Lung Cancer Manag. 9(3) (2020), LMT38.

15.

Bassi

, Russomando

, Vannucci

et al. Role of radiomics in predicting lung cancer spread through air spaces in a heterogeneous dataset, Transl Lung Cancer Res. 11(4) (2022), 560–571.

16.

Cong

, Feng

, Ren

J.L.

et al. Development of a predictive radiomics model for lymph node metastases in pre-surgical CT-based stage IA non-small cell lung cancer, , Lung Cancer 139 (2020), 73–79.

17.

C.C.

, Yeh

L.R.

, Kuo

Y.T.

et al. Imaging biomarkers for evaluating tumor response: RECIST and beyond, Biomark Res 9(1) (2021), 52.

18.

Zerunian

, Caruso

, Zucchelli

et al. CT based radiomic approach on first line pembrolizumab in lung cancer, Sci Rep 11(1) (2021), 6633.